CITIUS ONCOLOGY, INC. - 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Citius Oncology, Inc. (Nasdaq: CTOR) on April 25, 2025, regarding an event dated April 23, 2025. The Company is an emerging growth company incorporated in Delaware with principal executive offices in Cranford, NJ.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on a regulatory listing matter.
Material Changes and Listing Status
On April 23, 2025, Nasdaq notified the Company that its common stock bid price had closed below the $1.00 per share minimum requirement for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). Consequently, the Company has been granted an initial 180-day compliance period ending October 20, 2025, to regain compliance.
Outlook, Risks, and Management Commentary
- Compliance Path: To regain compliance, the stock must close at $1.00 or more for ten consecutive business days before October 20, 2025.
- Secondary Compliance Period: If the initial period is unsuccessful, the Company may be eligible for an additional 180-day period, contingent on meeting market value of publicly held shares and other initial listing standards. This may require a reverse stock split.
- Delisting Risk: Failure to regain compliance by the required deadlines could result in delisting. The Company may appeal such a determination to a Nasdaq hearings panel.
- Current Status: The notice has no immediate effect on the listing; the stock continues to trade on the Nasdaq Capital Market under the symbol "CTOR".
- Management Action: The Company is currently evaluating options to regain compliance, though there is no assurance of success.
Key Facts for Investor Verification
- Verify the current bid price of CTOR stock relative to the $1.00 threshold.
- Monitor the Company's announcement regarding a potential reverse stock split if the initial compliance period is not met.
- Check for updates on the market value of publicly held shares, which is a requirement for the second compliance period.
- Review the Company's cash position to assess its ability to fund operations while addressing the listing deficiency.